Country for PR: United States
Contributor: PR Newswire New York
Wednesday, November 06 2019 - 21:01
EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports
PROVIDENCE, Rhode Island, Nov. 6, 2019 /PRNewswire-AsiaNet/ --

EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces 
the publication of "Therapeutic administration of Tregitope-Human Albumin 
Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance 
Induction" in Scientific Reports, 06 Nov 2019 ( 
), a Nature publication.  This research highlights Tregitopes as a promising 
therapy for Type 1 Diabetes (T1D).  Administration of Tregitopes in combination 
with clinically relevant delivery systems and preproinsulin (PPI) were found to 
reduce the incidence of severe diabetes and to reverse mild diabetes during a 
49-day therapeutic study in non-obese diabetic mice.

Logo - 

Tregitopes are novel peptides first discovered in 2008 in human immunoglobulin 
by Dr. Anne De Groot and William Martin at EpiVax. They are capable of 
downregulating inflammation in a wide range of autoimmune disease models, 
transplant and allergy, by engaging regulatory T cells. This approach has been 
adapted by others seeking to harness the value of Tregitope, including Marieme 
Dembele of Dr. Bruce Mazer's lab, University of McGill, Montreal, Canada. 
Dembele will be presenting her findings on antigen specific tolerance induction 
by Tregitopes at the EpiVax Immunogenicity and Tolerance Seminar ( 
)on November 15th at Hilton Amsterdam, showing similar success in allergy 
models where Tregitope is delivered to aid in suppression of asthmatic 
symptoms. EpiVax is encouraged by these findings and looks forward to a 
continued bright future for the Tregitope program.

About EpiVax:
EpiVax is a 20-year old privately-held biotechnology company located in 
Providence, RI, with a broad portfolio of projects, including vaccines and 
immunotherapies for infectious diseases, autoimmunity and cancer. Scientists at 
EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in 
immunogenicity risk assessment. For more information, please visit

EpiVax is currently licensing Tregitope under 1-year options + license 
agreements. For more information on Tregitope and licensing opportunities, 
please contact us here ( 

For a free online version of this published research please visit Scientific 
Reports here ( 

Press Contact:
Dr. Anne De Groot, M.D. 
P: +1 (401) 272-2123
M: +1 (401) 952-4227

SOURCE: EpiVax, Inc.